In modern hospitals, many open heart surgical interventions are performed every day. Although cardiac surgery techniques have improved considerably over the last few years, a wide array of systemic and local infectious complications associated with these procedures have been reported \[[@CIT0001], [@CIT0002]\]. They are mainly local complications (eg, sternal wound infections), and overall bacterial etiology predominates \[[@CIT0003], [@CIT0004]\]. However, patients undergoing open heart surgery may also develop *Candida* bloodstream infections \[[@CIT0005], [@CIT0006]\].

*Candida* bloodstream infection (candidemia) has been associated with increased morbidity and mortality in critically ill patients \[[@CIT0007]\], and various general risk factors (eg, administration of broad-spectrum antibiotics, prolonged length of hospital stay, presence of a central venous catheter) have been extensively characterized \[[@CIT0020]\]. Nonetheless, specific populations of critically ill patients may present additional peculiar risk factors related to their medical or surgical reasons for intensive care unit (ICU) admission \[[@CIT0006], [@CIT0023]\]. Therefore, we conducted a case--control study in 8 hospitals in Italy to assess the predictors of candidemia after open heart surgery.

METHODS {#s1}
=======

Study Design and Objectives {#s2}
---------------------------

The present observational, retrospective case--control study was conducted in 8 Italian centers located in 7 different Italian regions. The study period was from January 1, 2009, to December 31, 2016. All patients who developed candidemia during the study period and during the ICU stay after open heart surgery were included as cases. Two controls without candidemia were matched to each case by the following criteria: (i) center; (ii) date of open heart surgery (±1 month); (iii) time at risk. For cases, time at risk was defined as the number of days elapsed from surgery to the onset of candidemia (ie, the day when the first blood culture positive for *Candida* spp. was drawn). For controls, time at risk was defined as the number of days elapsed from surgery to hospital discharge or in-hospital death. To avoid scarce fulfillment of the matching criterion, we arbitrarily set the time at risk in controls to be equal to or longer than the time at risk in cases minus 5 days. Cases were included in the study only once, at the time of the first episode of candidemia after open heart surgery.

The primary study objective was to assess factors associated with the development of postoperative candidemia. The assessment of predictors of crude mortality within 30 days after the onset of candidemia in cases was a secondary study objective. The study was approved by the ethical committee of the coordinating center (Ethical Committee of Liguria Region, registry number 320REG2017). The other participating centers followed the local ethical requirements.

Data Collection {#s3}
---------------

The following baseline data (preoperative and peri/intraoperative variables) were retrospectively collected from medical records and laboratory databases of the participating hospitals: age, gender, diabetes (defined as any preoperative diagnosis of diabetes mellitus requiring treatment), New York Heart Association (NYHA) class of heart failure, preoperative serum creatinine \>200 μmol/L, chronic obstructive pulmonary disease (COPD; defined as long-term use of bronchodilators or steroids for lung disease), history of immunosuppression (defined as 1 or more of the following: solid organ transplantation, malignancy, neutropenia \[absolute neutrophil count \<1000 cells/mm^3^\], HIV infection, chemotherapy within 45 days before surgery, therapy with ≥10 mg of prednisone or its equivalent per day for \>14 days before surgery), Charlson Comorbidity Index \[[@CIT0028]\], peripheral vascular disease (defined as ≥1 of the following: carotid occlusion or \>50% stenosis, claudication, amputation for arterial disease, previous or planned intervention on the abdominal aorta, carotids, or limb arteries), preoperative stroke (defined as any focal or global neurological syndrome caused by ischemia or hemorrhage not resolving within 24 hours), previous acute myocardial infarction (within 3 months), left ventricular ejection fraction (LVEF), EuroSCORE II \[[@CIT0029]\], type of open heart surgery (categorized as isolated coronary artery bypass surgery, isolated valvular surgery, surgery of thoracic aorta, or other/combined procedures), preoperative mechanical ventilation, pacemaker implantation, cardiopulmonary bypass (CPB) time in minutes, aortic cross-clamp time in minutes, sequential organ failure assessment (SOFA) score at the time of surgery \[[@CIT0030]\], need for peri/intraoperative blood transfusions.

The following data were also collected over the duration of the time at risk for candidemia in both cases and controls (postoperative variables): presence of central venous catheter for \>48 hours, receipt of total parenteral nutrition for \>48 hours, hemodialysis therapy for \>48 hours, administration of broad-spectrum antibiotics for \>48 hours, *Candida* colonization (defined as isolation of *Candida* spp. from nonsterile sites in absence of signs and symptoms of infection), bacterial bloodstream infections (defined as isolation of bacteria from blood in presence of signs and symptoms of infections, at least 2 positive cultures were required for coagulase-negative staphylococci).

The following data were also collected for cases (candidemia-related variables): species of *Candida* isolated from blood, presence of septic shock at the time of candidemia (according to Sepsis-3 criteria \[[@CIT0031]\]), removal of central venous catheter within 48 hours after the onset of candidemia, administration of antifungal therapy within 48 hours after the onset of candidemia.

Microbiology {#s4}
------------

*Candida* spp. were identified using the VITEK 2 automated system (bioMérieux, Marcy l'Etoile, France) or by MALDI-TOF mass spectrometry (bioMérieux, Marcy l'Etoile, France, or Bruker Daltonik, Bremen, Germany), according to the standard laboratory diagnostic procedures adopted in the different participating centers.

Statistical Analysis {#s5}
--------------------

The primary study analysis was the identification of factors associated with the development of candidemia after open heart surgery. To this aim, demographic and clinical variables were first tested for their association with the dependent variable (development of candidemia) in univariable conditional logistic regression models for matched pairs/sets, with strata composed by sets of single cases and their 2 matched controls \[[@CIT0032]\]. Then, variables associated with the development of candidemia in univariable comparisons (*P* \< .05) were included in an initial multivariable, conditional logistic regression model for matched pairs/sets and further selected for the final multivariable model by means of a stepwise backward procedure. A secondary study analysis was the identification of factors associated with crude 30-day mortality in candidemia cases. To this aim, we employed univariable and multivariable comparisons as for the primary analysis, with the exception of using unconditional logistic regression models. The analyses were performed using SPSS Statistics, version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS {#s6}
=======

Overall, 222 patients were included in the study (74 cases and 148 controls). Strict application of matching criteria was possible for 56% of controls (83/148). Owing to the absence of other controls fulfilling all 3 matching criteria, the remaining 44% (65/148) were selected as those with the nearest date of surgery (with respect to cases) outside the matching period (ie, beyond ± 1 month) but still fulfilling the matching criteria for center and time at risk.

During the study period, 36~ ~476 open heart surgery procedures were performed in the participating centers. The cumulative incidence of postoperative candidemia over the study period was of 2.03 episodes per 1000 open heart surgery patients. The median age of patients with candidemia (interquartile range \[IQR\]) was 72 (64--78) years, and 55% were males. The median time to development of candidemia (IQR) was 23 (14--36) days after surgery. Concomitant *Candida* endophthalmitis was diagnosed in 1% of cases (1/74). No concomitant *Candida* endocarditis was observed. Most candidemia episodes were due to *C. albicans* (48/74, 65%), followed by *C. parapsilosis* (10/74, 14%) and *C. glabrata* (7/74, 9%).

[Table 1](#T1){ref-type="table"} shows the results of univariable and multivariable analyses of factors associated with the development of candidemia. In univariable analysis, NYHA class III or IV, previous stroke, low LVEF, higher EuroSCORE II score, preoperative mechanical ventilation, hemodialysis therapy, SOFA score at the time of surgery, previous therapy with cephalosporins, previous therapy with carbapenems, previous therapy with fluoroquinolones, and multifocal *Candida* colonization had a statistically significant association with the development of candidemia. In the final multivariable model, NYHA class III or IV (odds ratio \[OR\], 23.81; 95% CI, 5.73--98.95; *P* \< .001), previous therapy with carbapenems (OR, 8.87; 95% CI, 2.57--30.67; *P* = .001), and previous therapy with fluoroquinolones (OR, 5.73; 95% CI, 1.61--20.41; *P* = .007) retained an independent association.

###### 

Univariable and Multivariable Analyses of Factors Associated With the Development of Candidemia After Open Heart Surgery

                                                                                                   Univariable Analysis     Multivariable Analysis^a^                         
  ------------------------------------------------------- -------------------- ------------------- ------------------------ --------------------------- --------------------- --------
  Preoperative and peri/intraoperative variables                                                                                                                              
   Age, median (IQR), y                                   72 (64--78)          72 (64--77)         1.00 (0.98--1.03)        .932                                              
   Male gender                                            41 (55)              99 (67)             0.64 (0.37--1.11)        .113                                              
   Diabetes mellitus                                      23 (31)              29 (20)             1.80 (0.96--3.39)        .067                                              
   NYHA class III/IV                                      53 (72)              40 (27)             6.26 (3.21--12.21)       \<.001                      23.81 (5.73--98.95)   \<.001
   Preoperative serum creatinine \>200 μmol/L             29 (39)              42 (28)             1.63 (0.90--2.95)        .105                                              
   COPD                                                   22 (30)              36 (24)             1.34 (0.70--2.56)        .372                                              
   History of immunosuppression                           1 (1)                9 (6)               0.20 (0.02--1.64)        .133                                              
   Charlson Comorbidity Index, median (IQR)               5 (3--7)             5 (3--6)            1.08 (0.95--1.23)        .232                                              
   Peripheral vascular disease                            14 (19)              27 (18)             1.04 (0.52--2.10)        .905                                              
   Previous stroke                                        12 (16)              8 (5)               4.00 (1.38--11.57)       .010                        4.61 (0.68--31.28)    .118
   Previous IMA                                           13 (18)              31 (21)             0.83 (0.42--1.62)        .577                                              
   LVEF, median (IQR), %                                  50 (37--55)          55 (45--55)         0.97 (0.95--1.00)        .031                        \-                    .633
   EuroSCORE II                                           6.61 (3.67--16.43)   3.51 (1.86--8.37)   1.06 (1.02--1.10)        .001                        \-                    .177
   Preoperative MV                                        16 (22)              9 (6)               3.56 (1.57--8.05)        .002                        \-                    .275
   Type of surgery                                                                                                          .073                                              
    Isolated coronary artery bypass surgery               6 (8)                22 (15)             (ref)                                                                      
    Isolated valvular surgery                             32 (43)              48 (32)             2.43 (0.88--6.71)                                                          
    Surgery of thoracic aorta                             26 (35)              41 (28)             2.13 (0.78--5.82)                                                          
    Other/combined procedures                             10 (14)              37 (25)             0.93 (0.29--2.97)                                                          
   Pacemaker implantation                                 2 (3)                10 (7)              0.40 (0.09--1.83)        .237                                              
   CPB time, median (IQR), min                            136 (98--208)        136 (92--197)       1.00 (1.00-1.00)         .843                                              
   Aortic cross-clamp time, median (IQR), min             75 (49--120)         87 (58--120)        1.00 (0.99--1.00)        .127                                              
   SOFA score at time of surgery, median (IQR)            4 (1--7)             3 (0--4)            1.19 (1.07--1.34)        .002                        1.20 (0.99--1.45)     .058
   Need for peri/intraoperative blood transfusion         61 (82)              124 (84)            0.85 (0.33--2.22)        .854                                              
   Need for \>5 peri/intraoperative blood transfusions    47 (64)              86 (58)             1.56 (0.69--3.52)        .288                                              
  Postoperative (during time at risk)                                                                                                                                         
   Central venous catheter \>48 h                         74 (100)             141 (95)            (model not converging)   \-                                                
   Total parenteral nutrition \>48 h                      42 (57)              86 (58)             0.94 (0.50--1.74)        .833                                              
   Hemodialysis \>48 h                                    27 (37)              28 (19)             2.55 (1.32--4.91)        .005                        \-                    .566
   Therapy with cephalosporins \>48 h                     18 (24)              12 (8)              4.65 (1.81--11.94)       .001                        \-                    \-
   Therapy with carbapenems \>48 h                        52 (70)              51 (35)             4.49 (2.37--8.49)        \<.001                      8.87 (2.57--30.67)    .001
   Therapy with fluoroquinolones \>48 h                   49 (66)              51 (35)             5.78 (2.64--12.65)       \<.001                      5.73 (1.61--20.41)    .007
  * Candida* colonization                                 29 (39)              45 (30)             1.52 (0.83--2.80)        .178                                              
  * Candida* multifocal colonization (at least 2 sites)   19 (26)              14 (10)             2.95 (1.43--6.12)        .004                        \-                    .723
   Bacterial BSI^b^                                       23 (31)              38 (26)             1.30 (0.69--2.47)        .415                                              

Results are presented as No. (%) unless otherwise indicated.

Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; IMA, acute myocardial infarction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association.

^a^Odds ratio and 95% CI are presented only for variables retained in the final multivariable model (ie, NYHA class III/IV, previous stroke, SOFA score at time of surgery, therapy with fluoroquinolones \>48 hours, therapy with carbapenems \>48 hours).

^b^Coagulase-negative staphylococci (n = 24), *Klebsiella* spp. (n = 8), *Staphylococcus aureus* (n = 6), *Enterobacter* spp. (n = 3), *Pseudomonas* spp. (n = 3), *Enterococcus* spp. (n = 2), and other bacteria with lower frequencies (n = 15).

Thirty-day crude mortality in patients with candidemia was 53% (39/74), whereas the crude in-hospital mortality of controls was 15% (22/148; chi-square test, *P* \< .001). The results of univariable and multivariable analyses of factors associated with 30-day mortality in patients with candidemia are shown in [Table 2](#T2){ref-type="table"}. In univariable analysis, \>5 peri/intraoperative blood transfusions, previous therapy with fluoroquinolones, and septic shock at the onset of candidemia were associated with increased 30-day mortality. Only septic shock, observed in as many as 36% of patients with candidemia, retained an independent association with the outcome in the final multivariable model (OR, 5.64; 95% CI, 1.91--16.63; *P* = .002).

###### 

Univariable and Multivariable Analyses of Factors Associated With 30-Day Mortality in Open Heart Surgery Patients With Postoperative Candidemia

                                                                                                    Univariable Analysis     Multivariable Analysis^b^                        
  ------------------------------------------------------ --------------------- -------------------- ------------------------ --------------------------- -------------------- ------
  Preoperative and peri/intraoperative variables                                                                                                                              
   Age, median (IQR), y                                  75 (67--79)           68 (60--76)          1.03 (0.99--1.08)        .129                                             
   Male gender                                           21 (54)               20 (57)              0.88 (0.35--2.19)        .776                                             
   Diabetes mellitus                                     11 (28)               12 (34)              0.75 (0.28--2.02)        .573                                             
   NYHA class III/IV                                     29 (74)               24 (69)              1.33 (0.48--3.66)        .582                                             
   Preoperative serum creatinine \>200 μmol/L            17 (44)               12 (34)              1.48 (0.58--3.80)        .414                                             
   COPD                                                  12 (31)               10 (29)              1.11 (0.41--3.02)        .836                                             
   History of immunosuppression                          1 (3)                 0 (0)                (model not converging)   \-                                               
   Charlson Comorbidity Index, median (IQR)              5 (3--7)              5 (2--6)             1.09 (0.90--1.32)        .390                                             
   Peripheral vascular disease                           7 (18)                7 (20)               0.88 (0.27--2.80)        .822                                             
   Previous stroke                                       7 (18)                5 (14)               1.31 (0.38--4.59)        .670                                             
   Previous IMA                                          10 (26)               3 (9)                3.68 (0.92--14.69)       .065                                             
   LVEF, median (IQR), %                                 50 (35--55)           48 (39--55)          1.00 (0.96--1.04)        .984                                             
   EuroSCORE II                                          13.57 (4.07--21.93)   4.57 (3.43--10.34)   1.05 (1.00--1.10)        .052                                             
   Preoperative MV                                       10 (26)               6 (17)               1.67 (0.54--5.19)        .378                                             
   Type of surgery                                                                                                           .898                                             
    Isolated coronary artery bypass surgery              4 (10)                2 (6)                (ref)                                                                     
    Isolated valvular surgery                            16 (41)               16 (46)              0.50 (0.08--3.13)                                                         
    Surgery of thoracic aorta                            14 (36)               12 (34)              0.58 (0.09--3.76)                                                         
    Other/combined procedures                            5 (13)                5 (14)               0.50 (0.06--4.09)                                                         
   Pacemaker implantation                                1 (3)                 1 (3)                0.90 (0.05--14.86)       .938                                             
   CPB time, median (IQR), min                           136 (98--198)         137 (93--213)        1.00 (1.00-1.00)         .652                                             
   Aortic cross-clamp time, median (IQR), min            73 (51--110)          89 (49--140)         1.00 (0.99--1.01)        .603                                             
   SOFA score at time of surgery, median (IQR)           4 (1--7)              3 (1--6)             1.02 (0.89--1.17)        .749                                             
   Need for peri/intraoperative blood transfusion        32 (82)               29 (83)              0.95 (0.29--3.14)        .928                                             
   Need for \>5 peri/intraoperative blood transfusions   29 (74)               18 (51)              2.74 (1.03--7.28)        .043                        \-                   .151
  Postoperative variables (during time at risk)                                                                                                                               
   Central venous catheter \>48 h                        39 (100)              35 (100)             \-                       \-                                               
   Total parenteral nutrition \>48 h                     25 (64)               17 (49)              1.89 (0.75--4.80)        .180                                             
   Hemodialysis \>48 h                                   16 (41)               11 (31)              1.52 (0.58--3.95)        .393                                             
   Therapy with cephalosporins \>48 h                    10 (26)               8 (23)               1.16 (0.40--3.38)        .781                                             
   Therapy with carbapenems \>48 h                       26 (67)               26 (74)              0.69 (0.25--1.90)        .475                                             
   Therapy with fluoroquinolones \>48 h                  30 (77)               19 (54)              2.81 (1.03--7.62)        .043                        \-                   .115
  * Candida* colonization                                13 (33)               16 (46)              0.59 (0.23--1.52)        .278                                             
  * Candida* multifocal colonization (≥2 sites)          9 (23)                10 (29)              0.75 (0.26--2.13)        .590                                             
   Bacterial BSI^b^                                      9 (23)                14 (40)              0.45 (0.17--1.23)        .120                                             
  Candidemia-related variables                                                                                                                                                
   Septic shock                                          21 (54)               6 (17)               5.64 (1.91--16.63)       .002                        5.64 (1.91--16.63)   .002
   Causative *Candida* species                                                                                               .184                                             
    *albicans*                                           28 (74)               20 (59)              (ref)                                                                     
    Non-*albicans*^c^                                    10 (26)               14 (41)              0.51 (0.19--1.38)                                                         
   Early antifungal therapy (within 48 h^d^)             13 (33)               16 (46)              0.59 (0.23--1.52)        .278                                             
   Early CVC removal (within 48 h^d^)                    13 (33)               14 (40)              0.75 (0.29--1.94)        .552                                             

Results are presented as No. (%) unless otherwise indicated.

Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CVC, central venous catheter; IMA, acute myocardial infarction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association.

^a^Odds ratio and 95% CI are presented only for the variables retained in the final multivariable model (ie, septic shock).

^b^Coagulase-negative staphylococci (n = 8), *Klebsiella* spp. (n = 5), *Pseudomonas* spp. (n = 3), *Staphylococcus aureus* (n = 2), other bacteria with lower frequencies (n = 5).

^c^Two nontyped species were not included in the comparison *albicans* vs non-*albicans* species. Typed non-*albicans* species were as follows: *C. parapsilosis* (n = 10), *C. glabrata* (n = 7), *C. tropicalis* (n = 3), *C. krusei* (n = 2), *C. dubliniensis* (n = 1), *C. sake* (n = 1).

^d^After the onset of candidemia (ie, the day when the first positive blood culture for *Candida* spp. was drawn).

DISCUSSION {#s7}
==========

In this retrospective, multicenter, case--control study, high NYHA class, previous therapy with carbapenems, and previous therapy with fluoroquinolones were associated with the development of candidemia after open heart surgery.

Risk factors for developing candidemia after open heart surgery have also been explored by other studies. Michalopoulos and colleagues conducted a single-center, case--control study in 150 cardiac surgery patients (30 cases with postoperative candidemia and 120 controls without candidemia) \[[@CIT0024]\]. Controls were matched to cases according to gender, body mass index, agents administered for general anesthesia and for postoperative sedation, type of employed cardioplegia, and CPB technique. Independent predictors of candidemia were mechanical ventilation \>10 days, hospital-acquired bacterial infection and/or bacteremia, CPB time \>120 minutes, and diabetes mellitus \[[@CIT0024]\]. Subsequently, Pasero and colleagues assessed risk factors for candidemia in a cohort of patients admitted to a cardiac surgery ICU \[[@CIT0006]\]. Among 349 patients, 26 developed candidemia. Independent predictors of candidemia were ICU length of stay \>20 days, total parenteral nutrition, severe sepsis, and high simplified acute physiology score (SAPS II), whereas no association with development of candidemia was observed for CPB time \[[@CIT0006]\].

Similar to Pasero and colleagues, we did not find an association between prolonged CPB and development of postoperative candidemia (thus apparently not being in line with the hypothesis of an enhanced intestinal permeability related to prolonged CPB-related ischemia, with possible increased risk of translocation of bacteria and/or fungi from the intestinal lumen to the bloodstream) \[[@CIT0033]\]. In the interpretation of this results, it should be kept in mind that in our study we focused on a subpopulation of cardiac surgery patients (ie, those with prolonged postoperative ICU stay). Indeed, candidemia mostly developed late during ICU stay (and thus the length of postoperative ICU stay was inherently long, also in matched controls), a fact that is in line with the well-known role of prolonged hospital stay as a general predictor of candidemia \[[@CIT0005], [@CIT0006], [@CIT0020], [@CIT0023], [@CIT0024]\]. Overall, this may suggest that CPB time is not helpful for discriminating the risk of candidemia (absolutely or vs that of bacterial BSI \[[@CIT0035]\]) in cardiac surgery patients with prolonged ICU stay, that is, in those who usually are the most likely to develop candidemia because they already express classical, non-surgery-related risk factors. For example, our results confirm that the previous administration of broad-spectrum antibiotics is an important risk factor for candidemia in cardiac surgery patients, in line with the results of previous studies conducted in more general populations \[[@CIT0020], [@CIT0022], [@CIT0023], [@CIT0036]\], and potentially explained by the disruptive effect that previous broad-spectrum antibiotics may have on the human microbiota with consequent increased risk of *Candida* translocation \[[@CIT0039]\]. In addition, we found a high baseline NYHA class to be an independent predictor of postoperative candidemia. This finding warrants further investigation, as this predisposing factor was not investigated in other studies assessing predictors of candidemia in cardiac surgery patients. However, it remains reasonable that a high NYHA class may represent a proxy for a higher burden of comorbidity or need for more intensive care procedures, possibly and generally influencing the risk of postoperative infections.

As a secondary analysis, we assessed the predictors of 30-day mortality in patients with postoperative candidemia. In this regard, the independent association we observed between septic shock and mortality further confirms the importance of the severity of clinical presentation in unfavorably influencing the outcome \[[@CIT0017]\]. On the other hand, caution is needed before interpreting the absence of other independent predictors of mortality in our analysis. For example, early antifungal therapy and early CVC removal have been previously indicated as important predictors of survival \[[@CIT0007], [@CIT0040]\], and it is worth noting that a trend toward improved survival for these 2 factors was also appreciable in our univariable results, although it did not reach statistical significance (possibly because of reduced power). Finally, it is of note that the low cumulative incidence of candidemia we found was similar to that observed in surgical ICUs in a recent European multicenter study \[[@CIT0017]\], possibly reflecting the presence in the denominator of a high number of patients with short postoperative ICU stay and consequent low risk of candidemia.

This study has some important limitations. The most important are related to its retrospective nature and mainly consist of possible information biases (eg, we did not systematically register the number of performed ophthalmologist evaluations and echocardiograms in cases, although they are considered standard procedures in our centers). Another limitation is that we were unable to retrospectively collect sufficient data and/or adjustments for time at risk for some postoperative intensive care procedures (eg, use of intra-aortic balloon pump) and some postoperative noninfectious complications (eg, reoperations for bleeding) that may have influenced the risk of infection. Two other important limitations are the lack of long-term follow-up in survivors of candidemia \[[@CIT0026]\] and the use of a single control group instead of 2 different control groups to separately assess (i) the predictors of candidemia vs no infection and (ii) the predictors of candidemia vs bacteremia. Finally, although increased with respect to previous studies, the power of our primary analysis remains somewhat suboptimal; thus we may have failed to detect other true associations that could be clinically relevant. Nonetheless, to our knowledge this is the largest cohort of candidemic cardiac surgery patients (n = 74) employed for assessing the risk of postoperative candidemia, and it may add valuable information to the literature, complementary to that of previous studies with more limited sample sizes.

In conclusion, previous broad-spectrum antibiotic therapy and high NYHA class were independent predictors of candidemia in cardiac surgery patients with prolonged postoperative ICU stay, whereas no association between prolonged CPB time and candidemia was observed in the present case--control study. Further studies are needed to explore the possible role of CPB-related ischemia in influencing the risk of candidemia episodes occurring early after surgery.
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